Full Text View
Tabular View
Study Results
Related Studies
Prevention of Restenosis Following Revascularization
This study has been terminated.
( Study was terminated due to changing sponsor priorities, and was not based on safety or outcomes data. )
Study NCT00518284   Information provided by Celgene Corporation

First Received on August 16, 2007.   Last Updated on February 21, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Vascular Disease, Peripheral
Additional conditions recognized in this trial
Peripheral Arterial Disease
Peripheral Vascular Diseases
Vascular Diseases
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Atherosclerosis
Cardiovascular Diseases
Interventions listed in this trial
Nanoparticle Paclitaxel
Additional drug interventions recognized in this trial
Paclitaxel
More general drug interventions related to this trial
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Celgene Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services